EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma

Recently, tyrosine kinase inhibitors (TKIs) have been recommended as a first-line treatment for advanced non-small cell lung cancer (NSCLC), significantly improving the treatment outcomes of lung adenocarcinoma patients with the EGFR mutation. However, the application of TKIs for lung squamous cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Memon, Aadil Ahmed, Zhang, Haiping, Gu, Ye, Luo, Qian, Shi, Jiajun, Deng, Zixin, Ma, Jian, Ma, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609803/
https://www.ncbi.nlm.nih.gov/pubmed/29075127
http://dx.doi.org/10.2147/OTT.S130051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609803/
https://www.ncbi.nlm.nih.gov/pubmed/29075127
http://dx.doi.org/10.2147/OTT.S130051

Ejemplares similares